FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The FDA has issued draft guidance that could speed up approval pathways for rare disease therapies using genome editing technologies. This framework is directly relevant to CRISPR Therapeutics, which focuses on CRISPR/Cas9 based treatments. The guidance, once finalized, may influence how quickly rare disease candidates progress through regulatory review. For CRISPR Therapeutics (NasdaqGM:CRSP), this regulatory move comes at a time when the stock trades around $55.2, with a 24.3% return over the past year and a 15.7% return over the past 3 years. The longer term picture is more mixed, with a 53.6% decline over the past 5 years, so many investors are watching for catalysts that could reshape expectations around its rare disease pipeline. If the draft guidance eventually translates into clearer and more efficient review paths, it could influence how investors thin
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit [Yahoo! Finance]Yahoo! Finance
- Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]Seeking Alpha
- CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/17/26 - Form SCHEDULE
- CRSP's page on the SEC website